

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number	09/875,456
Filing Date	June 6, 2000
First Named Inventor	Qin, et al.
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	ORT-1448

MAY

83

2002

TECH CENTER 1600/2900

RECEIVED
JULY 13 2002
U.S. PATENT AND TRADEMARK OFFICE

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		BALSER, JEFFREY R, STRUCTURE AND FUNCTION OF THE CARDIAC SODIUM CHANNELS, <i>Cardiovascular Research</i> (1999) 42:327-338
		Catterall, William A, CELLULAR AND MOLECULAR BIOLOGY OF VOLTAGE-GATED SODIUM CHANNELS, <i>Pharmaceutical Rev.</i> , Vol. 22, No. 4 (1991) William A., STRUCTURE AND FUNCTION OF VOLTAGE-GATED ION CHANNELS, <i>Trends Neurosci</i> 16:5-506 (1993)
2		Chabal, Charles, et al., THE EFFECT OF INTRAVENOUS LIDOCAINE, TOCAINIDE, AND MEXILETINE ON SPONTANEOUSLY ACTIVE FIBERS ORIGINATING IN RAT SCIATIC NEUROMAS, <i>Pain</i> , 38 (199) 333-338
		Chaplan, S.R., et al., QUANTITATIVE ASSESSMENT OF TACTILE ALLODYNIA IN THE RAT PAW, <i>Journal of Neuroscience Methods</i> 53 (1994) 55-63
		D'Andrea, Michael R., et al. CHARACTERIZATION OF PROTEASE-ACTIVATED RECEPTOR-2 IMMUNOREACTIVITY IN NORMAL HUMAN TISSUES, <i>Journal of Histochemistry & Cytochemistry</i> , Vol. 46(2): 157-164 (1998)
		Devor, Marshall et al., NA ⁺ CHANNEL ACCUMULATION ON AXOLEMMA OF AFFERENT ENDINGS IN NERVE END NEUROMAS IN APTERONOTUS, <i>Neuroscience Letters</i> , 102 (1989) 149-154
		Devor, Marshall, THE PATHOPHYSIOLOGY OF DAMAGED PERIPHERAL NERVES, In <i>Textbook of Pain</i> , eds. 79-101 (1994)
		Devor, Marshall, et al. SYSTEMIC LIDOCAINE SILENCES ECTOPIC NEUROMA AND DRG DISCHARGE WITHOUT BLOCKING NERVE CONDUCTION, <i>Pain</i> , 48 (1992) 261-268
8		Dib-hajj, et al. Down-Regulation of Transcripts for Na Channel α -SNS IN SPINAL SENSORY NEURONS FOLLOWING AXOTOMY, <i>Neurobiology</i> (1996) Vol. 93, 14950-14954.
		Ecker, David J., et al., INCREASING GENE EXPRESSION IN YEAST BY FUSION TO UBIQUITIN, <i>Journal of Biological Chemistry</i> Vol. 264, 7715-7719 (1986)
2		England JD, Gamboni F, Ferguson MA, Levinson SR (1994) Sodium channels accumulate at the tips of injured axons. <i>Muscle Nerve</i> 17:593-598.
9		England, J.D., et al. (1996) SODIUM CHANNEL ACCUMULATION IN HUMANS WITH PAINFUL NEUROMAS, <i>American Academy of Neurology</i> , 47:272-276.
		Gould, Harry J. III, et al., RAPID SODIUM CHANNEL AUGMENTATION IN RESPONSE TO INFLAMMATION INDUCED BY COMPLETE FREUND'S ADJUVANT, <i>Brain Research</i> 802 (1998) 69-74
		Horowitz, et al., SYNTHESIS AND ASSEMBLY OF FUNCTIONAL MAMMALIAN Na,K-ATPase IN YEAST, <i>Journal of Biological Chemistry</i> (1990)
		Isom, L.L., et al. PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF THE β_1 SUBUNIT OF THE RAT BRAIN SODIUM CHANNEL, <i>Science</i> (1992), Vol. 356.
		ISOM, L.L., et al. STRUCTURE AND FUNCTION OF THE β_2 SUBUNIT OF BRAIN SODIUM CHANNELS, A TRANSMEMBRANE GLYCOPROTEIN WITH A CAM MOTIF, <i>Cell</i> , Vol. 83 (1995) 433-442
		ISOM, L.L., et al. AUXILIARY SUBUNITS OF VOLTAGE-GATED ION CHANNELS, <i>Neuron</i> , (1994), Vol 12 1183-1194
7		Jacobson, et al., EXPRESSION AND SECRETION OF BIOLOGICALLY ACTIVE ECHISTATIN IN SACCHAROMYCES CEREVIAE, <i>Gene</i> (1989) 51-516
2		KAZEN-GILLESPIE, et al., CLONING, LOCALIZATION, AND FUNCTIONAL EXPRESSION OF SODIUM CHANNEL β_1 SUBUNITS, <i>Journal of Biological Chemistry</i> (2000) Vol. 275 No. 2 1079-1088
9		Kim, et al. AN EXPERIMENTAL MODEL FOR PERIPHERAL NEUROPATHY PRODUCED BY SEGMENTAL SPINAL NERVE LIGATION IN THE RAT, <i>Pain</i> (1992), 355-363
		Kitts, Paul A., et al., LINEARIZATION OF BACULOVIRUS DNA ENHANCES THE RECOVERY OF RECOMBINANT VIRUS EXPRESSION VECTORS, <i>Nucleic Acids Research</i> (1990), 5667-5672
		Marban, et al., STRUCTURE AND FUNCTION OF VOLTAGE-GATED SODIUM CHANNELS, <i>Journal of Physiology</i> (1998), 647-657
		Matzner et al., Na ⁺ CONDUCTANCE AND THE THRESHOLD FOR REPETITIVE NEURONAL FIRING, <i>Brain Research</i> (1992) 92:98
		Matzner O, Devor M (1994) Hyperexcitability at sites of nerve injury depends on voltage-sensitive Na ⁺ channels. <i>J Neurophysiol</i> 72:349-359.

Examiner Signature	<i>JL</i>	Date Considered	3-11-02
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

02 JAN 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	09/875,456
Filing Date	June 6, 2001
First Named Inventor	Qin, et al.
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	ORT-1448

1	MCDONNELL, D. et al. RECONSTRUCTION OF THE VITAMIN D-RESPONSIVE OSTEOCALCIN TRANSCRIPTION UNIT IN SACCHAROMYCES CEREVISIAE, Molecular & Cellular Biology, (1989) Vol. 9 No. 8: 3517-3523
2	NORDIN, et al., ECTOPIC SENSORY DISCHARGES AND PARESTHESIAE IN PATIENTS WITH DISORDERS OF PERIPHERAL NERVES, DORSAL ROOTS AND DORSAL COLUMNS, Pain 20 (1984), 231-245
2	OCHOA, et al., PARAESTHESIAE FROM ECTOPIC IMPULSE GENERATION IN HUMAN SENSORY NERVES, Brain (1980) 103, 835-853
2	Oh, Youngsuk, et al., Na ⁺ Channel β 1 SUBUNIT mRNA; DIFFERENTIAL EXPRESSION IN RAT SPINAL SENSORY NEURONS, Molecular Brain Research, (1995) 357-361
2	Omana-Zapata, Imelda, et al., TETRADOTOXIN INHIBITS NEUROPATHIC ECTOPIC ACTIVITY IN NEUROMAS, DORSAL ROOT GANGLIA AND DORSAL HORN NEURONS, Pain 72 (1997) 41-49
2	Poreca, Frank, et al., A COMPARISON OF THE POTENTIAL ROLE OF THE TETRADOTOXIN-SENSITIVE SODIUM CHANNELS, PN3/SNS AND NAN/SNS2, IN RAT MODELS OF CHRONIC PAIN, Proc. Natl. Acad. Sci., USA, Vol. 96 (1999) 7640-7644
2	Rieh-Bellon, Nadine et al., PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF RECOMBINANT HIRUDIN PRODUCED BY SACCHAROMYCES CEREVISIAE, Biochemistry (1989) 2941-2949
2	Rinas, Ursula, et al., CHARACTERIZATION OF RECOMBINANT FACTOR XIIIa PRODUCED IN SACCHAROMYCES CEREVISIAE, Biotechnology (1990), 543-546
2	Rizzo, Marco A., SUCCESSFUL TREATMENT OF PAINFUL TRAUMATIC MONONEUROPATHY WITH CARBAMAZEPINE; INSIGHTS INTO A POSSIBLE MOLECULAR PAIN MECHANISM, Journal of Neurological Sciences, (1997) 103-106
2	SABIN, E. et al., HIGH-LEVEL EXPRESSION AND IN VIVO PROCESSING OF CHIMERIC UBIQUITIN FUSION PROTEINS IN SACCHAROMYCES CEREVISIAE, Biotechnology (1989) Vol. 7: 705-709
2	Sleep, D. et al., THE SECRETION OF HUMAN SERUM ALBUMIN FROM THE YEAST SACCHAROMYCES CEREVISIAE USING FIVE DIFFERENT LEADER SEQUENCES, Biotechnology, Vol. 8 (1990) 42-45
2	Sutkowski et al., β 1 SUBUNITS OF SODIUM CHANNELS, The Journal of Biological Chemistry (1990)12393-12399
2	Tanaka, M., et al., SNS NA ⁺ CHANNEL EXPRESSION INCREASES IN DORSAL ROOT GANGLION NEURONS IN THE CARRAGEENAN INFLAMMATORY PAIN MODEL, Molecular Neuroscience, vol. 9 (1998) 967-972
2	Wallace, R. H., et al., FEBRILE SEIZURES AND GENERALIZED EPILEPSY ASSOCIATED WITH A MUTATION IN THE NA ⁺ CHANNEL β 1 SUBUNIT GENE SCN1B, Nature America Inc. (1998), 368-370
2	Waxman, Stephen, et al., CONDUCTIN THROUGH DEMYELINATED PLAQUES IN MULTIPLE SCLEROSIS; COMPUTER SIMULATIONS OF FACILITATION BY SHORT INTERNODES, Journal of Neurology, Neurosurgery, and Psychiatry (1978) 408-416
2	Waxman, S.G., et al., SODIUM CHANNELS AND PAIN, Proc. Natl. Acad. Sci., USA, 1999 Vol 96 7635-7639
2	WAXMAN SG, ET AL. (1994) TYPE III SODIUM CHANNEL mRNA IS EXPRESSED IN EMBRYONIC BUT NOT ADULT SPINAL SENSORY NEURONS, AND IS REEXPRESSED FOLLOWING AXOTOMY. J NEUROPHYSIOL 72:466-470.
2	Woolf CJ, et al., (1994) Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62:327-331.
2	Yamamoto, Yoshio et al., IMPORTANT ROLE OF THE PROLINE RESIDUE IN THE SIGNAL SEQUENCE THAT DIRECTS THE SECRETION OF HUMAN LYSOZYME IN SACCHAROMYCES CEREVISIAE, American Chemical Society (1989), 2728-2732

Examiner
Signature

Jorin

Date
Considered

3-31-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Qin et al.

Serial No. : 09/875,456

Art Unit: 1653

Filed : June 6, 2001

Examiner:

For :

RECEIVED

MAY 03 2002

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, Washington, D.C. 20231 on

December 31, 2001

(Date of Deposit)

Myra McCormack,

(Name of applicant, assignee, or Registered Representative)

(Signature)

December 31, 2001

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, therefore:

Statement in Accordance with §1.97(e) (attached);
or
 Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- Statement in Accordance with §1.97(e) (attached);
or
- Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
 - In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
 - If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
- There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1448/MHM. This form is submitted in triplicate.

Respectfully submitted,

Myra McCormack
Reg. No. 36602
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATED: December 31, 2001